Permira to buy small molecule company Cambrex for £1.97bn
As per terms of the merger deal, Cambrex shareholders will secure $60 (£49.3) in cash for each share of Cambrex common stock, representing a 47.1% premium to its
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
Givosiran, which has been developed to be subcutaneously administered, targets aminolevulinic acid synthase 1 (ALAS1). According to Alnylam, monthly administration of the investigational RNAi therapeutic can potentially reduce
The collaboration includes the availability of HCL’s Faster Intelligent Trials (FIT) Solution using Oracle Health Sciences Mobile Health (mHealth) Connector Cloud Service (Oracle mHealth Cloud). HCL’s FIT solution
The study has achieved its co-primary endpoint of investigator-assessed progression-free survival (PFS). Roche’s combination of Tecentriq plus platinum-based chemotherapy demonstrated a statistically significant reduction in the risk of